Page 149 - Haematologica May 2022

DA-EPOCH-R in double expressor lymphoma
died (n=20 for disease progression, n=1 for toxicity, n=1 sui- cide). PFS (95% confidence interval [CI]) and OS at 2-year were 74% (66-83%) and 84% (77-91%), respectively (Figure 1A and B). The 2-year OS and PFS were not signifi-
cantly different between DEL, DEL-MYC, DEL-BCL2 and, DEL-DH/TH, with a trend for inferior survival in this last subgroup (OS: 66% [range, 47-92%], P=0,058) (Figure 1C and D).
AB
CD
EF
Figure 1. Kaplan-Meier estimates of progression-free survival and overall survival. Progression-free survival (A, C and E) and overall survival (B, D and F) for the whole cohort (A and B) and according to rearrangements (C and D). DEL: double expressor lymphomas only; DEL-MYC, DEL-BCL2: high-grade lymphomas (double- hit/triple-hit [DH/TH]) and International Prognostic Index (panels E and F).
haematologica | 2022; 107(5)
1157